• DUET: TMC 114 and 125 for Drug-Resistant HIV
• TMC 114 Expanded Access Program
• IMPACT: Reyataz Resistance
• Pregabalin for Peripheral Neuropathy
• TH9507 for Lipodystrophy (Closed to Enrollment)
• Maraviroc for Drug-Resistant HIV (Closed to Enrollment)

DUET: TMC 114 and 125 for Drug-Resistant HIV

People who are resistant to PIs and NNRTIs will take TMC125 (a new NNRTI) or a placebo (dummy) pill. Everyone will also take TMC114 (a new PI) with Norvir and other anti-HIV drugs. Participants must be 18 or older and have a viral load over 5,000.

TMC 114 Expanded Access Program

People who have taken anti-HIV drugs from three of the four classes of drugs (an NRTI, NNRTI and two PIs), and who have limited or no treatment options due to resistance or intolerance, will take TMC 114 (a new PI) along with other anti-HIV drugs. Participants must be 18 or older, have a CD4 count below 200 and must not be eligible for the DUET study.

IMPACT: Reyataz Resistance

People who have developed resistance to Reyataz will come in for one day of blood tests to study the I50L mutation.

Pregabalin for Peripheral Neuropathy

People with HIV who have peripheral neuropathy will take either pregabalin (Lyrica) or a placebo (dummy pill) for 3 months. Participants must be 18 or older and have had pain in their hands or feet for at least 3 months.

For the above trials, contact Dr. Douglas Mendez at 212-924-3934 ext. 126 or Dr. Yuriy Akulov at ext. 124.

TH9507 for Lipodystrophy (Closed to Enrollment)

People who have excess abdominal fat and who are taking anti-HIV drugs will take either TH9507 (an experimental growth hormone releasing factor) or a placebo for 26 weeks.

Maraviroc for Drug-Resistant HIV (Closed to Enrollment)

People who have taken anti-HIV drugs from three of the four classes of drugs will either take maraviroc (an experimental HIV attachment inhibitor) or placebo with an optimized regimen of anti-HIV drugs for 11 months.